Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
For Biotech R&D Groups
Preclinical biotech and pharma discovery teams source characterized peptides for receptor-pharmacology, screening, and method development — then need the same material at larger scale on a locked route. Lyochem countersigns an NDA fast, runs non-standard modifications, and carries a pilot lot through to preclinical scale-up without changing the synthesis route underneath you.
The situation
Discovery procurement has two failure modes: a custom sequence that arrives uncharacterized, and a pilot lot that cannot be reproduced at scale. Both stall a campaign. The fix is a supplier who treats identity verification and route-locking as part of the deliverable, not an upsell.
Lyochem works custom from the sequence up — PEGylation, lipidation, metal chelation, fluorescent and isotope labels, disulfide bridging — and documents the route so the pilot lot and the scale-up lot are the same molecule. NDAs are countersigned within a business day so the sequence conversation can start immediately.
Regions served: USA · EU · UK · Switzerland · Singapore · APAC discovery hubs
How procurement runs
Mutual NDA countersigned within one business day; share the sequence and modifications and we scope feasibility and the analytical strategy.
A characterized pilot lot with the full identity packet for your bench validation before any scale commitment.
Once validated, the synthesis route is locked so the scale-up lot matches the pilot at the residue and impurity-profile level.
Preclinical scale-up runs against your timeline; forecast-based reservation absorbs sponsor-driven date shifts.
The release packet
The analytical packet — not the price — is what an audit, a reviewer, or a downstream SOP actually checks. Request the sample data packet to vet the depth before a PO.
Mutual NDA countersigned within one business day
Modification scope: PEG, lipidation, metal chelation, fluorescent + isotope labels, disulfide bridging
Per-lot RP-HPLC + ESI-MS, with LC-MS/MS sequence confirmation
Impurity profile so pilot and scale-up lots are comparable
Locked synthesis route from pilot to preclinical scale
Stability series tuned to the downstream protocol on request
Curated catalogue
GIP / GLP-1 / glucagon tri-agonist · 39-mer metabolic research peptide
GIP / GLP-1 dual receptor agonist · 39-mer metabolic research peptide
Long-acting amylin analog · metabolic research peptide
GLP-1 receptor agonist · 31-mer metabolic research peptide
EPO-derived 11-mer · cytoprotective research peptide
16-mer
Mitochondrial-derived peptide
Before a first order
A mutual NDA is countersigned within one business day, so the sequence and modification conversation can begin immediately. From there we scope feasibility, the analytical strategy, and a pilot-lot timeline before any commitment.
Routine scope includes PEG conjugation, fatty-acid lipidation, metal (e.g. copper) chelation, fluorescent and isotope labels, D-amino-acid incorporation, intramolecular disulfide bridging, and N/C-terminal modifications. Share the target and we confirm feasibility and the verification approach for that construct.
That is the point of locking the route. Once you validate the pilot, the synthesis route is fixed so the scale-up lot matches at the sequence and impurity-profile level. Each lot still ships with its own identity packet so you can confirm equivalence directly.
Yes — forecast-based reservation lets us hold against an expected window so a sponsor-driven date shift does not push you to the back of the queue. Discuss the forecast at quote stage.
Lab notes for this workflow
Lab Note
Custom Peptide Synthesis — When to Commission, When to Use a Catalog Standard
Read
Comparison
Semaglutide vs Tirzepatide vs Retatrutide vs Cagrilintide: A Research Sourcing Comparison
Read
Methodology
How to Verify GLP-1 and Metabolic Peptides by HPLC and MS
Read
Lab Note
Retention-Time Identity Is Not Sequence Identity — When the Difference Matters
Read
Other research teams we serve
Academic Laboratories
Universities, medical schools, and government institutes qualifying a reference standard for a method-development or in-vivo workflow.
View
Contract Research Organisations
CROs running preclinical and translational studies for sponsors who need traceable reference material reconciled across multi-site campaigns.
View
Core Facilities & Instrumentation Cores
Shared instrumentation cores and mass-spec facilities holding reference standards for cross-PI method validation and reagent qualification.
View
First reply under 12 hours from a synthesis chemist or analytical contact — not a templated auto-response. Lot-specific HPLC chromatogram, ESI-MS identity, MS/MS sequence (on request), KF water, and stability data returned with the quote.